As we delve deep into countless medical journals to uncover the latest on Integrative Medicine’s approach to kidney health, we are always reminded of the value of your time. Our commitment remains steadfast in curating and succinctly summarizing these vital studies for you. Welcome to the July Research and News.
DASH4D Trial: Sodium Reduction Plus DASH-Style Diet Lowers Blood Pressure in Type 2 Diabetes
In the DASH4D randomized crossover trial of 102 adults with type 2 diabetes, researchers tested the effects of a modified DASH-style diet optimized for diabetes (DASH4D) and sodium reduction on blood pressure.
Participants followed four controlled 5-week diets: DASH4D or a typical U.S. diet, each with high or low sodium.
Compared to a high-sodium typical diet, the DASH4D diet with reduced sodium lowered systolic blood pressure by 4.6 mm Hg and diastolic by 2.3 mm Hg. Most reductions occurred in the first 3 weeks and were mainly attributed to sodium reduction, even among those on multiple antihypertensive medications.
Why is this important?
People with type 2 diabetes are at high cardiovascular risk, and this trial demonstrates that dietary sodium reduction, even without weight loss, can meaningfully lower blood pressure. The findings reinforce the importance of dietary strategies alongside pharmacologic treatment in managing hypertension in diabetes.
Elevated TSH Causally Linked to Reduced Kidney Function: A Mendelian Randomization Study
This multivariable Mendelian randomization (MVMR) study explored the causal relationship between thyroid function and kidney health using data from over 17,000 participants in the Taiwan Biobank and was validated in European populations.
Elevated thyroid-stimulating hormone (TSH) levels and hypothyroidism were associated with lower estimated glomerular filtration rate (eGFR), while thyroid peroxidase antibodies (TPOAb) showed a positive correlation with eGFR.
MVMR confirmed a causal effect of higher TSH, but not fT4 or TPOAb, on reduced kidney function, reinforcing the role of thyroid dysfunction in chronic kidney disease (CKD).
Why is this important?
These findings suggest that thyroid dysfunction, particularly elevated TSH levels, may directly impair kidney function. Recognizing and managing thyroid abnormalities could offer a new avenue for slowing CKD progression and optimizing patient care.
Reducing Dietary Phosphorus Additives Lowers FGF23 and PTH in Adults with CKD
This controlled feeding study examined how cutting phosphorus additives in the diet affects mineral metabolism in 50 adults with and without CKD.
After two weeks on a phosphorus–additive–enhanced diet, participants transitioned to a low-additive diet for six weeks.
In both groups, 24-hour urine phosphorus excretion dropped by ~30%. In the CKD group, fibroblast growth factor 23 (FGF23) levels declined by 25% and parathyroid hormone (PTH) by 20%.
Among healthy individuals, FGF23 decreased significantly only in White participants, not in Black participants, indicating a race-based difference in response.
Why is this important?
Excess dietary phosphorus from additives may worsen mineral imbalances that contribute to CKD progression and cardiovascular risk. This study shows that reducing phosphorus additives can improve key metabolic markers, especially in those with CKD, highlighting a practical, diet-based strategy for managing kidney health.
Join us to end the kidney disease epidemic
Urine Alkalization Enhances Gout Management Beyond Uric Acid Control
This prospective cohort study investigated whether adding urine alkalization to urate-lowering therapy (ULT) improves outcomes in men with gout and low urinary pH (<6.2).
A total of 385 participants initiating febuxostat therapy were divided into groups based on whether they also received a citrate mixture for urine alkalization.
At 12 weeks, the alkalization group showed a significantly lower urine albumin-to-creatinine ratio (UACR), fewer gout flares, lower pain scores, and improved lipid profiles (lower triglycerides, higher HDL-C), despite requiring lower febuxostat doses. Serum urate targets and eGFR were similar between groups.
Why is this important?
While xanthine oxidase inhibitors like febuxostat lower serum urate, they don’t address urine acidity, which contributes to urate crystal formation and renal microvascular damage.
This study provides evidence that targeting urinary pH may offer complementary benefits, including reduction in albuminuria, an early marker of kidney damage, and mitigation of gout flares and metabolic dysfunction.
By reducing the need for higher drug doses and improving lipid metabolism, urine alkalization with products like Ketocitra or potassium citrate offers a low-risk, cost-effective adjunct that could help personalize gout and kidney disease management, particularly in patients with features of metabolic syndrome.
COVID-19 Vaccination and De Novo Glomerular Disease: International Registry Insights
This international registry study (IRocGN2) analyzed 98 cases of new-onset glomerular disease (GD) suspected to be temporally associated with COVID-19 vaccination, collected from 44 centers globally.
IgA nephropathy (IgAN) and minimal change disease (MCD) were the most commonly reported post-vaccine glomerular pathologies, especially following mRNA-based vaccines.
Other reported conditions included membranous nephropathy, pauci-immune GN, and collapsing glomerulopathy, sometimes presenting as dual pathologies.
Median follow-up was 89 days post-diagnosis. Patients with IgAN and MCD experienced more favorable outcomes, exhibiting higher rates of kidney function recovery and proteinuria remission at 4–6 months compared to those with other forms of GN.
Why is this important?
This study provides the most comprehensive global data to date on glomerular diseases potentially linked to COVID-19 vaccination. While causality remains unproven, the consistent temporal pattern and histologic trends, particularly the predominance of IgAN and MCD, raise important questions about immune activation pathways triggered by vaccination.
Importantly, the overall kidney outcomes were favorable, especially for these two subtypes, supporting the continued safety and utility of COVID-19 vaccination. These findings help clinicians weigh rare risks against substantial public health benefits and underscore the value of post-vaccine surveillance for vulnerable patients, including those with prior renal or autoimmune conditions.
Review article of the month
Effects of microplastics and nanoplastics on the kidney and cardiovascular system
Microplastics and nanoplastics are pervasive environmental pollutants found in air, food, and water, leading to widespread human exposure and accumulation in organs such as the heart, kidney, liver, and brain. Research in animal models and human cells shows that these particles can trigger oxidative stress, inflammation, metabolic disruption, and immune dysfunction.
This review article examines the toxic effects of these compounds on kidney and cardiovascular cells, with a heightened risk for individuals undergoing dialysis. Additionally, particulate plastic exposure has been linked to cardiovascular disease. Mitigation strategies include improved waste management, use of alternative materials, filtration technologies, and regulatory reforms, underscoring the urgent need for further research on their health impacts.
Join here to receive FREE monthly updates on the latest research in Integrative Nephrology and tips on managing kidney disease straight to your inbox.
We would love to hear your feedback. Let us know what you think of these educational materials and if you would like us to focus on specific topics. Please email us at info@inkidney.com.
